192 related articles for article (PubMed ID: 12548250)
21. Effect of a second-generation venous catheter impregnated with chlorhexidine and silver sulfadiazine on central catheter-related infections: a randomized, controlled trial.
Rupp ME; Lisco SJ; Lipsett PA; Perl TM; Keating K; Civetta JM; Mermel LA; Lee D; Dellinger EP; Donahoe M; Giles D; Pfaller MA; Maki DG; Sherertz R
Ann Intern Med; 2005 Oct; 143(8):570-80. PubMed ID: 16230723
[TBL] [Abstract][Full Text] [Related]
22. Decreasing catheter-related infection and hospital costs by continuous quality improvement.
Civetta JM; Hudson-Civetta J; Ball S
Crit Care Med; 1996 Oct; 24(10):1660-5. PubMed ID: 8874302
[TBL] [Abstract][Full Text] [Related]
23. Rifampicin-impregnated central venous catheters: a meta-analysis of randomized controlled trials.
Falagas ME; Fragoulis K; Bliziotis IA; Chatzinikolaou I
J Antimicrob Chemother; 2007 Mar; 59(3):359-69. PubMed ID: 17255143
[TBL] [Abstract][Full Text] [Related]
24. Antimicrobial-impregnated central venous catheters.
Schutze GE
Pediatr Infect Dis J; 2002 Jan; 21(1):63-4. PubMed ID: 11791103
[No Abstract] [Full Text] [Related]
25. Efficacy of antiseptic-impregnated catheters on catheter colonization and catheter-related bloodstream infections in patients in an intensive care unit.
Osma S; Kahveci SF; Kaya FN; Akalin H; Ozakin C; Yilmaz E; Kutlay O
J Hosp Infect; 2006 Feb; 62(2):156-62. PubMed ID: 16307824
[TBL] [Abstract][Full Text] [Related]
26. Cost effectiveness of antimicrobial catheters in the intensive care unit: addressing uncertainty in the decision.
Halton KA; Cook DA; Whitby M; Paterson DL; Graves N
Crit Care; 2009; 13(2):R35. PubMed ID: 19284570
[TBL] [Abstract][Full Text] [Related]
27. Prevention of bloodstream infections with central venous catheters treated with anti-infective agents depends on catheter type and insertion time: evidence from a meta-analysis.
Walder B; Pittet D; Tramèr MR
Infect Control Hosp Epidemiol; 2002 Dec; 23(12):748-56. PubMed ID: 12517018
[TBL] [Abstract][Full Text] [Related]
28. The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation.
Hockenhull JC; Dwan K; Boland A; Smith G; Bagust A; Dündar Y; Gamble C; McLeod C; Walley T; Dickson R
Health Technol Assess; 2008 Apr; 12(12):iii-iv, xi-xii, 1-154. PubMed ID: 18405471
[TBL] [Abstract][Full Text] [Related]
29. Improved antibiotic-impregnated catheters with extended-spectrum activity against resistant bacteria and fungi.
Raad I; Mohamed JA; Reitzel RA; Jiang Y; Raad S; Al Shuaibi M; Chaftari AM; Hachem RY
Antimicrob Agents Chemother; 2012 Feb; 56(2):935-41. PubMed ID: 22123686
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial durability and rare ultrastructural colonization of indwelling central catheters coated with minocycline and rifampin.
Raad II; Darouiche RO; Hachem R; Abi-Said D; Safar H; Darnule T; Mansouri M; Morck D
Crit Care Med; 1998 Feb; 26(2):219-24. PubMed ID: 9468157
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis.
Veenstra DL; Saint S; Saha S; Lumley T; Sullivan SD
JAMA; 1999 Jan; 281(3):261-7. PubMed ID: 9918482
[TBL] [Abstract][Full Text] [Related]
32. Antimicrobial-impregnated central venous catheters.
Maury E; Offenstadt G
N Engl J Med; 1999 Jun; 340(22):1761-2; author reply 1762. PubMed ID: 10357632
[No Abstract] [Full Text] [Related]
33. Prevention of intravascular catheter-related infections.
Mermel LA
Ann Intern Med; 2000 Mar; 132(5):391-402. PubMed ID: 10691590
[TBL] [Abstract][Full Text] [Related]
34. Commentary: zero tolerance for catheter-related bloodstream infections: the unnegotiable objective.
Raad II
Infect Control Hosp Epidemiol; 2008 Oct; 29(10):951-3. PubMed ID: 18754737
[No Abstract] [Full Text] [Related]
35. Efficiency of chlorhexidine-silver sulfadiazine-impregnated venous catheters at subclavian sites.
Lorente L; Lecuona M; Jiménez A; Lorenzo L; Santacreu R; Ramos S; Hurtado E; Buitrago M; Mora ML
Am J Infect Control; 2015 Jul; 43(7):711-4. PubMed ID: 25934065
[TBL] [Abstract][Full Text] [Related]
36. In vitro evaluation of the antibacterial activity of three different central venous catheters against gram-positive bacteria.
Yorganci K; Krepel C; Weigelt JA; Edmiston CE
Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):379-84. PubMed ID: 12072923
[TBL] [Abstract][Full Text] [Related]
37. Chlorhexidine-silver sulfadiazine-impregnated venous catheters save costs.
Lorente L; Lecuona M; Jiménez A; Santacreu R; Raja L; Gonzalez O; Mora ML
Am J Infect Control; 2014 Mar; 42(3):321-4. PubMed ID: 24581021
[TBL] [Abstract][Full Text] [Related]
38. New technologies to prevent intravascular catheter-related bloodstream infections.
Mermel LA
Emerg Infect Dis; 2001; 7(2):197-9. PubMed ID: 11294705
[TBL] [Abstract][Full Text] [Related]
39. Impregnated central venous catheters for prevention of bloodstream infection in children (the CATCH trial): a randomised controlled trial.
Gilbert RE; Mok Q; Dwan K; Harron K; Moitt T; Millar M; Ramnarayan P; Tibby SM; Hughes D; Gamble C;
Lancet; 2016 Apr; 387(10029):1732-42. PubMed ID: 26946925
[TBL] [Abstract][Full Text] [Related]
40. The evolving technology of venous access.
Wenzel RP; Edmond MB
N Engl J Med; 1999 Jan; 340(1):48-50. PubMed ID: 9878645
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
